Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pain, Postoperative 2Breast Neoplasms 2Pancreatic Neoplasms 1Pain 1Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Breast Diseases 1

Interventions

Fluorouracil 34Cisplatin 34Radiotherapy 30Oxaliplatin 30Paclitaxel 22pembrolizumab 20Irinotecan 20Docetaxel 20Leucovorin 19Capecitabine 16Cetuximab 11Carboplatin 11Bevacizumab 11Radiation 10Surgical Procedures, Operative 9Trastuzumab 8Panitumumab 6Epirubicin 6Neoadjuvant Therapy 5Esophagectomy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4tisotumab vedotin 3durvalumab 3Sunitinib 3Microarray Analysis 3Immunohistochemistry 3Gene Expression Profiling 3Gemcitabine 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × Botulinum Toxins, Type A × Clear all
NCT02965976 2023-02-16

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Roswell Park Cancer Institute

Phase 2 Completed
33 enrolled 17 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡